Evidence map›Paper›PMID 21741270›Full record

ReviewSeminars in immunology2011

Tolerogenic dendritic cells and their role in transplantation.

Mohamed Ezzelarab, Angus W Thomson

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Immune regulation of the ocular surface.Experimental eye research · 2022
    Review
  13. Xenotransplantation: A New Era.Frontiers in immunology · 2022
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mohamed EzzelarabThomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, BST W1540, Pittsburgh, PA 15261, USA.
Angus W Thomson
University of Pittsburgh · US

Funding

RHESUS MONKEY DENDRITIC CELLS FOR TRANSPLANT TOLERANCEU01AI051698 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2002 to 2011
$4.9M
Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in MonkeysU01AI091197 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2010 to 2016
$4.3M
Liver Antigen - Presenting Cells in Hepatic Injury and TransplantationP01AI081678 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2009 to 2010
$2.8M
Dendritic Cells, Rapamycin and Transplant ToleranceR01AI067541 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2007 to 2010
$1.7M
LIVER TRANSPLANTATION: THE ROLE OF DENDRITIC CELLSR01DK049745 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 1996 to 2005
$1.4M
NIAID NIH HHS P01 AI081678NIAID NIH HHS P01 AI81678NIAID NIH HHS R01 AI067541NIAID NIH HHS R01 AI67541NIAID NIH HHS U01 AI051698NIAID NIH HHS U01 AI091197NIAID NIH HHS U01 AI51698NIAID NIH HHS U01 AI91197NIDDK NIH HHS R01 DK049745
6 · The paper itself

Abstract

The pursuit of clinical transplant tolerance has led to enhanced understanding of mechanisms underlying immune regulation, including the characterization of immune regulatory cells, in particular antigen-presenting cells (APC) and regulatory T cells (Treg), that may play key roles in promoting operational tolerance. Dendritic cells (DC) are highly efficient APC that have been studied extensively in rodents and humans, and more recently in non-human primates. Owing to their ability to regulate both innate and adaptive immune responses, DC are considered to play crucial roles in directing the alloimmune response towards transplant tolerance or rejection. Mechanisms via which they can promote central and peripheral tolerance include clonal deletion, the induction of Treg, and inhibition of memory T cell responses. These properties have led to the use of tolerogenic DC as a therapeutic strategy to promote organ transplant tolerance. In rodents, infusion of donor- or recipient-derived tolerogenic DC can extensively prolong donor-specific allograft survival, in association with regulation of the host T cell response. In clinical transplantation, progress has been made in monitoring DC in relation to graft outcome, including studies in operational liver transplant tolerance. Although clinical trials involving immunotherapeutic DC for patients with cancer are ongoing, implementation of human DC therapy in clinical transplantation will require assessment of various critical issues. These include cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy. With ongoing non-human primate studies focused on DC therapy, these logistics can be investigated seeking the optimal approaches. The scientific rationale for implementation of tolerogenic DC therapy to promote clinical transplant tolerance is strong. Evaluation of technical and therapeutic logistic issues is an important next step prior to the application of tolerogenic DC in clinical organ transplantation.

Indexed as

Cell- and Tissue-Based TherapyOrgan TransplantationAnimalsAntigen PresentationChemotherapy, AdjuvantClinical Trials as TopicDendritic CellsGraft RejectionGraft SurvivalHumansImmune ToleranceImmunosuppression TherapyModels, AnimalPrimatesT-Lymphocytes, Regulatory

Identifiers

PMID21741270
PMCPMC3192911
OpenAlexW2085521487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.